During fertility treatment, oestrogen concentrations can rise many times above the levels usually seen during a menstrual cycle. Around menopause, women may instead be prescribed oestrogen to relieve symptoms arising as ovarian hormone production changes.
Both treatments require medical judgements about benefits and risks. Yet menopausal hormone therapy has a particularly contested history, shaped by high expectations, serious concerns and changing recommendations.
On social media, this contrast has inspired the claim that women have been frightened away from hormone therapy. A widely circulated post compares oestradiol concentrations during IVF with those seen during menopausal treatment. Its message is that society accepts hormones when the goal is pregnancy but responds with suspicion when the aim is women's own health and quality of life later on.
The comparison raises important questions. But it also assumes that the risks can be compared directly and that women's concerns stem mainly from how hormone therapy has been discussed. The history of the evidence is more complicated.
What is oestrogen, and what does it do?
Oestrogen is a family of naturally occurring hormones that affect much more than reproduction. The three principal natural forms are oestradiol (E2), the most active during the reproductive years and produced mainly in the ovaries; oestrone (E1), which becomes relatively more important after menopause and can be formed in fatty tissue; and oestriol (E3), a weaker oestrogen that rises markedly during pregnancy as the placenta contributes to production.
Oestrogens bind to receptors – specialised structures in cells that respond to hormones – throughout the body. They contribute to bone turnover, affect the brain's temperature-regulating systems and help maintain the thickness, moisture and elasticity of vaginal and urinary tissues. They also influence blood vessels and lipid metabolism.
The hormone's natural actions must be distinguished from the proven effects of medical treatment. That oestrogen influences an organ does not automatically mean giving the hormone prevents disease in that organ.
How oestrogen changes over a lifetime
Oestrogen is usually low before puberty and rises as the reproductive system develops. During the reproductive years, oestradiol fluctuates through the menstrual cycle, generally peaking before ovulation. Levels of oestrogens rise considerably during pregnancy.
As menopause approaches, hormone production becomes more irregular. This transitional period is called perimenopause and may last several years. Menopause refers to the final menstrual period, normally confirmed retrospectively after twelve months without natural menstruation. Oestradiol production from the ovaries then settles at a lower level.
Some women have few symptoms. Others experience hot flushes, night sweats, sleep problems and symptoms affecting vaginal or urinary tissues. Declining oestrogen can also increase bone loss and contribute to osteoporosis, a weakening of bones that raises fracture risk.
Why are hormones used in fertility treatment?
In vitro fertilisation (IVF) aims to achieve pregnancy by fertilising eggs outside the body and transferring an embryo into the uterus. Usually, the ovaries are stimulated to mature several eggs at once, increasing the number available for collection and fertilisation.
In a natural menstrual cycle, several follicles start developing, but generally only one releases a mature egg. This process is regulated partly by follicle-stimulating hormone (FSH) and luteinising hormone (LH), made in the pituitary gland beneath the brain. IVF medicines act on these hormonal systems, allowing more follicles to develop.
As follicles grow, the ovaries themselves produce more oestradiol. High oestradiol during IVF is therefore generally a consequence of ovarian stimulation, rather than injections of equivalent amounts of oestradiol. In some women, blood levels may reach 3,000–5,000 picograms per millilitre (pg/mL). A picogram is a tiny unit of mass used to measure hormone concentrations.
These levels are not evidence that high hormone exposure is risk-free. A strong response can increase the risk of ovarian hyperstimulation syndrome (OHSS), in which the ovaries enlarge and fluid may collect in the abdomen. Severe cases may cause circulatory problems, impaired kidney function and blood clots. Fertility teams therefore assess age, ovarian reserve, follicle development and response to adjust treatment and reduce risks. The goal is a pregnancy achieved through safe care, not the highest possible oestrogen concentration.
Why is oestrogen used around menopause?
Around menopause, falling and fluctuating ovarian oestradiol may affect sleep, concentration, employment and daily life. Hormone therapy can relieve these symptoms.
Systemic hormone therapy acts throughout the body and may be administered through patches, gels, sprays or tablets. It can reduce hot flushes, night sweats and other symptoms associated with hormonal changes.
Women who still have a uterus generally take progesterone or a progestogen alongside systemic oestrogen. Progesterone is produced naturally; progestogens are medicines with similar actions. They protect the uterine lining from abnormal growth and reduce the risk of endometrial cancer.
Local vaginal oestrogen is used for dryness, soreness and discomfort affecting vaginal and urinary tissues. It acts mainly where applied, with much less absorption into the rest of the body.
Systemic therapy also reduces bone loss and osteoporotic fractures while used. Women who experience menopause before 45 may be advised to take hormones until around the expected age of natural menopause, partly for long-term health. Duration depends on individual symptoms, health, treatment response and preferences.
The same hormone, different medical circumstances
Both IVF stimulation and menopausal hormone treatment involve oestradiol, but this similarity tells only part of the story.
During IVF, ovarian oestradiol production can rise sharply for a limited period. Around menopause, oestrogen may be supplied as medicine over a number of years to relieve symptoms.
A blood concentration is not the same as a medicine dose. Blood tests measure hormone concentration at a point in time, whereas dosage describes the amount administered. Absorption, duration of exposure and the involvement of other hormones all matter.
A high concentration during IVF does not establish that a lower level during menopausal treatment is automatically safe, or that menopausal therapy is generally more dangerous than fertility care.
Both treatments can be medically justified and both demand consideration of benefits and risks. Nevertheless, their place in public debate has differed. While IVF stimulation is often discussed in the context of having children, menopausal hormone therapy has for decades been debated in connection with ageing, disease prevention, breast cancer and access to care. To understand why, we need to examine the period before the major US Women's Health Initiative trial.
From promises of better health to fears of serious illness
Menopausal hormone therapy has long been linked to medical expectations and ideas about femininity and ageing.
In 1966, American gynaecologist Robert A. Wilson published Feminine Forever, portraying menopause as a hormone deficiency that oestrogen could correct, with promises of preserving youth, energy, sexuality and femininity.
The book helped popularise oestrogen treatment in the United States, although many claims went far beyond the available scientific evidence.
Later, observational studies suggested that women using hormones had a lower risk of some cardiovascular diseases. Observational studies follow people who have already chosen whether or not to use treatment. They can reveal associations but may not establish whether treatment itself caused an outcome.
Hormone users could differ from non-users in education, wealth, health status and access to care. Nevertheless, the findings fuelled expectations that hormones might prevent disease, even in women without troublesome menopausal symptoms.
Hormone therapy became widespread in the US during the 1990s. Oestrogen was portrayed as a way to preserve health well into old age, beyond treating symptoms. Randomised trials began challenging these expectations. In 1998, a study of women with established heart disease found that the hormone regimen tested did not provide the anticipated protection from further cardiac events.
Four years later, even more influential results arrived.
How one major study changed the discussion
In July 2002, the combined oestrogen-and-progestogen arm of the American Women's Health Initiative (WHI) was stopped earlier than planned.
WHI was a major research programme investigating approaches to disease prevention among postmenopausal women. Participants in this trial received conjugated oestrogens with medroxyprogesterone acetate, a progestogen, or placebo, a treatment without active medicine.
The hormone group experienced increased risks including breast cancer, blood clots and certain cardiovascular events. The findings attracted widespread international attention and changed prescribing practices.
But the trial examined specific drugs, doses and participants. Women were around 63 years old on average at the start, many years after menopause. The findings could not automatically be extended to every hormone preparation, age group or women starting closer to menopause. Nevertheless, WHI became a turning point.
When research findings reached the public
A US survey carried out shortly after the 2002 WHI results offers insight into women's reactions.
Among 819 women aged 40–79, 64% said they had heard about the findings through the media or other people. Some 74% reported confusion about hormone use and 57% were worried about how the findings might affect them.
The survey cannot represent every woman's experience. It was conducted in the US at a particular time, but it documents considerable uncertainty among respondents.
Prescribing also changed dramatically. A JAMA study published in 2004 found that the number of hormone prescriptions in the US fell by about 43% from the second quarter of 2002 to the fourth quarter of 2003.
That sharp fall followed the release of WHI findings, but cannot establish why each woman stopped, or whether stopping was the right decision for her.
Some women may have become unnecessarily concerned. Others may have received information about documented risk that reasonably affected their choices. That distinction matters.
Were women frightened away from hormone therapy?
The claim that women were frightened away from hormones has support in one observation: concerns increased and use fell sharply after WHI.
But the term gaslighting, used in the post that inspired this article, implies more than information causing fear. It usually describes manipulation that undermines a person's trust in their own experience or understanding.
Applying it to hormone therapy therefore implies systematic deception or dismissal. Research documents uncertainty, changing practice and sometimes absolute public messages; it does not establish that women's concerns in general resulted from deliberate manipulation.
Some risks identified by WHI were real. The results also challenged earlier claims that hormones should be used to prevent cardiovascular disease in healthy women. This was important evidence.
Later research showed that risks differed by age, timing, preparation and outcome. That raised questions about whether safety information had always been sufficiently precise.
Presenting results from one specific regimen as though they applied equally to every hormone product can mislead women. Yet emphasising benefits while downplaying risks can mislead them too. Both tendencies have appeared in the treatment's history.
How the presentation of risk shapes decisions
Medical risk can be expressed in different ways. Relative risk describes how much a probability rises or falls compared with another group. Absolute risk describes how many people are expected to experience the event.
If a risk rises from 2% to 3%, the relative increase is 50%, whereas the absolute increase is one percentage point – one additional event per 100 people. Both figures are accurate, but they can sound very different.
For hormone therapy this matters because baseline risks of breast cancer, blood clots and cardiovascular disease vary with age and health history. A percentage increase is less informative without knowing the starting risk.
Benefits also need to be described concretely. For a woman experiencing severe hot flushes, better sleep and daily functioning can be significant. For someone without symptoms, the balance is different.
Good risk communication explains what treatment helps, how large the risks are and what remains uncertain. Two women with comparable symptoms may make different decisions without either misunderstanding the evidence.
What does more recent research show?
Later studies have produced a more nuanced picture of menopausal hormone therapy. A 2024 JAMA review of WHI highlighted the importance of treatment purpose, preparation and age at initiation.
Randomised evidence still does not justify hormone therapy as general prevention of chronic disease. Systemic treatment is, however, the most effective therapy for moderate to severe hot flushes and night sweats.
Bone health: documented protection
Oestrogen helps regulate the formation and breakdown of bone. After menopause, declining oestrogen can accelerate bone loss.
Systemic menopausal hormone therapy reduces bone loss and osteoporotic fractures while taken. This is among its best-established longer-term benefits.
Other medicines and preventive measures are available. Choices depend on age, fracture risk, other conditions and menopausal symptoms.
The heart: timing can matter
Oestrogen influences blood vessels, cholesterol and cardiovascular processes, but its biological actions do not prove that hormone treatment prevents heart attacks or strokes.
Timing of treatment initiation appears relevant. For many healthy women under 60, or within ten years of menopause, benefits may outweigh risks when treatment is used for troublesome symptoms.
That does not mean all women should take oestrogen to prevent cardiovascular disease. A 2024 systematic review of 33 randomised trials illustrates why individual cardiovascular outcomes and treatment approaches must be assessed separately.
The brain: high hopes, continuing uncertainty
Oestrogen influences brain signalling, temperature regulation and processes involved in memory. Researchers have therefore explored whether therapy might influence cognitive decline and dementia.
A systematic review and meta-analysis published in December 2025 brought together ten studies involving more than one million people. A meta-analysis pools evidence from several studies.
The authors found no statistically significant overall association between hormone therapy and mild cognitive impairment or dementia. They advised that treatment should be considered for other demonstrated benefits and risks rather than prescribed to prevent dementia. Evidence gaps remain, including differences in treatment regimens and initiation timing.
Breast cancer: the preparation matters
Breast cancer risk remains one of the most debated aspects of hormone therapy.
A major 2019 analysis in The Lancet found increased risk with several forms of systemic treatment, particularly prolonged combined oestrogen–progestogen therapy compared with oestrogen alone. Duration and hormone combinations affect estimates.
The UK's NICE guidelines distinguish combined hormone therapy from oestrogen-only therapy. Risk increases with duration of combined treatment, while the risk increase with oestrogen alone is described as little or none.
Oestrogen alone is generally used by women who have had their uterus removed. For women with a uterus, unopposed systemic oestrogen can increase endometrial cancer risk.
Blood clots: the route matters
Systemic oestrogen can affect the risk of venous blood clots. These develop inside veins, often in the legs, and can sometimes travel to the lungs.
Research distinguishes oral tablets from preparations delivered through the skin. Oral oestrogen is associated with higher venous clot risk than patches, gels or sprays.
The route therefore matters to individual clinical decisions. Local vaginal oestrogen has far less systemic absorption and a different risk profile. It makes little sense to treat all forms of hormone therapy as one identical treatment.
Has the view of hormone therapy changed again?
Health authorities have increasingly distinguished between hormone preparations, routes and individual risk factors.
In November 2025, the US Food and Drug Administration (FDA) announced plans to revise menopause hormone therapy safety information. In February 2026, it approved changes for six products.
Warnings involving breast cancer, cardiovascular disease and probable dementia were removed from the boxed warning – the prominent framed section used to highlight serious risks in US prescribing information.
FDA's decision changes how some risks are presented; it does not mean they have disappeared. Information about relevant risks remains elsewhere in certain product labels. The agency also removed wording about using the lowest possible dose for the shortest period from the affected US labelling.
These changes concern US medicines and regulations.
What does this mean for women in Norway?
The Norwegian Medical Products Agency (DMP) is the national medicines authority within Norwegian and European regulation. FDA decisions do not automatically alter Norwegian product information or treatment guidance.
DMP continues to recommend individual assessment and use of the lowest effective dose for the shortest possible duration. Norway's Helsenorge also explains that there is no single fixed maximum duration for every woman: treatment needs to be reviewed in light of symptoms, benefits, risks and health.
The contrast illustrates how regulatory communication may differ. US decisions can influence international debate, but need to be understood in light of the specific medicines and legal systems concerned.
More women in Norway may receive reimbursement
Public attention to menopause care has increased in Norway. DMP states that approximately 300,000 Norwegian women use medicines for menopausal symptoms.
On 30 October 2026, DMP announced an expansion of automatic reimbursement for hormone treatment. The change is planned to take effect on 1 December 2026 and may make around 50,000 additional women with severe and lasting symptoms eligible for subsidised treatment.
Under the blue-prescription scheme, the public sector covers much of eligible medicine costs. The assessment draws in part on documented effects of systemic treatment for hot flushes and night sweats and local treatment for vaginal symptoms.
Other complaints, such as concentration difficulties and certain psychological symptoms, have a less clear evidence base for hormone treatment. This shapes which treatments public funds cover, raising broader questions about which health outcomes researchers have prioritised.
Have women's own experiences received enough attention?
The debate is also about who gets to define a need for treatment.
Some women have years of disrupted sleep, exhaustion, hot flushes and vaginal symptoms. Others have few significant symptoms.
Some want hormone treatment and benefit from it. Others experience side effects, have medical reasons to avoid it or prefer different approaches. These experiences can coexist.
Investigating whether women have adequate access to treatment differs from assuming more women necessarily ought to take hormones. The first concerns healthcare quality; the second requires evidence on symptoms, preferences, contraindications and individual risks.
When menopause affects working life
The impact of menopause extends beyond healthcare. A 2025 US study explored employees' experiences in a large workplace. Among respondents with current menopausal symptoms, only nine per cent reported receiving workplace support.
The study involved one organisation and cannot provide a representative estimate for women in Norway or the US as a whole. It nevertheless illustrates why accommodation, knowledge and support matter.
Hormone therapy may help some women, while others need different treatment or workplace adjustments. Access to good care is broader than receiving a particular prescription.
Do we value women's health differently when reproduction is involved?
The original social-media post contrasts fertility care with menopause treatment. Its implication is that society accepts medical risk to help women become mothers but questions risk when the aim is women's own quality of life.
This is a legitimate social question. Yet medical differences between the therapies do not themselves prove that women's reproductive capacity is valued above their health later in life.
IVF and menopausal therapy have different goals, durations and documented risks. At the same time, research funding, healthcare organisation and policy priorities can determine which needs attract attention.
To evaluate unequal prioritisation we would need comparative evidence on funding, treatment access, research and patient experiences.
Women also have widely differing experiences: some have never wanted children, some have undergone prolonged fertility treatment, and some experience early menopause after illness or medical treatment. Their needs deserve consideration on their own terms.
Which health benefits count?
The goal of fertility treatment is relatively clear: pregnancy. The value of menopausal treatment can be more complex.
How do we measure sleeping through the night, being able to work or participating in daily activities without repeated hot flushes? Research can assess these outcomes through symptom measures and quality-of-life questionnaires.
Health authorities must also assess the certainty and size of benefits, risks and the allocation of limited resources. Symptoms often have multiple causes. Hormone therapy may improve sleep when night sweats are a major factor, but benefits for unrelated sleep problems are less certain.
Evidence is also less conclusive for some cognitive and psychological symptoms. Lack of evidence for a particular treatment effect does not mean a person's symptoms are unimportant. It means more research is needed on causes and treatments.
Between medical risks and women's right to treatment
The history of hormone therapy shows how quickly medical expectations can change. In the 1960s oestrogen was promoted as preserving youth and femininity; in the 1990s, hopes focused more on disease prevention. After WHI in 2002, serious medical risks dominated the debate.
More recent research has produced more differentiated guidance, but public discussion can still be polarised.
Claims that hormones protect the whole body, prevent dementia or extend life may promise more than evidence supports. Conversely, general warnings can obscure situations in which treatment can genuinely help.
Evidence-based care needs to communicate risk without unnecessary fear, and benefits without exaggerated promises. Women need understandable information to consider options in light of their own circumstances, whether they choose hormones or alternatives.
Women's health throughout life
The claim that women were never afraid of hormones but were frightened away from them captures an important debate about medical information, trust and who defines women's treatment needs.
Research history shows that concerns have had different causes. Some were grounded in documented risks; others have been qualified by later evidence. Expectations of treatment, both past and present, have sometimes exceeded what research supports.
The essential question may be what women were told, how information was presented and what opportunities they had to make their own choices.
Good care requires more than prescribing or discouraging a medicine. Women's symptoms must be taken seriously, risks explained clearly and options based on current evidence.
How do we ensure women's health is taken seriously when their needs concern their own quality of life rather than reproduction?
That question matters regardless of which treatment an individual woman chooses. Good women's health concerns the whole body – throughout life.
